Bladder Cancer
April 2018 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Bladder Cancer abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Bladder Cancer. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Bladder Cancer. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Bladder Cancer every 3 months. Thank you for your ongoing subscription to this publication.

Sincerely,
Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:The clinical significance of COL5A2 in patients with bladder cancer: A retrospective analysis of bladder cancer gene expression data.
Authors:Zeng XT, Liu XP, Liu TZ, Wang XH
Institution:Department of Urology. University, Wuhan University, Wuhan, China. University, Wuhan University, Wuhan, China. University, Wuhan University, Wuhan, China.
Journal:Medicine (Baltimore). 2018 Mar;97(10):e0091. doi: 10.1097/MD.0000000000010091.

2:Immune checkpoint inhibitors for metastatic bladder cancer.
Authors:Massari F, Di Nunno V, Cubelli M, Santoni M, Fiorentino M, Montironi R, Cheng L, Lopez-Beltran A, Battelli N, Ardizzoni A
Institution:Division of Oncology, S.Orsola-Malpighi Hospital, Bologna, Italy. Electronic address: francesco.massari@aosp.bo.it. Bologna, Italy. School of Medicine, United Hospitals, Ancona, Italy. Medicine, Indianapolis, IN, USA. Spain.
Journal:Cancer Treat Rev. 2018 Mar;64:11-20. doi: 10.1016/j.ctrv.2017.12.007. Epub 2018 Jan 31.

3:Kidney, Ureteral, and Bladder Cancer: A Primer for the Internist.
Authors:Arora HC, Fascelli M, Zhang JH, Isharwal S, Campbell SC
Institution:Center for Urologic Oncology, Glickman Urological and Kidney Institute, Cleveland Clinic, 9500 Euclid Avenue, Q10-1, Cleveland, OH 44195, USA. Electronic address: campbes3@ccf.org.
Journal:Med Clin North Am. 2018 Mar;102(2):231-249. doi: 10.1016/j.mcna.2017.10.002.

4:Efficacy and Tolerability of Bacillus Calmette-Guerin Therapy as the First-Line Therapy for Upper Urinary Tract Carcinoma In Situ.
Authors:Tomisaki I, Kubo T, Minato A, Fujimoto N
Institution:a Department of Urology , University of Occupational and Environmental Health , 1-1 Iseigaoka Yahatanishi-ku Kitakyushu City Fukuoka , Japan.; b Department of Public Health , University of Occupational and Environmental Health , 1-1 Iseigaoka Yahatanishi-ku Kitakyushu City Fukuoka , Japan.
Journal:Cancer Invest. 2018 Feb 7;36(2):152-157. doi: 10.1080/07357907.2018.1430815. Epub 2018 Feb 2.

5:Pathology in repeated transurethral resection of a bladder tumor as a risk factor for prognosis of high-risk non-muscle-invasive bladder cancer.
Authors:Tae BS, Jeong CW, Kwak C, Kim HH, Moon KC, Ku JH
Institution:Department of Urology, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea. Korea. Korea. Korea. Korea.
Journal:PLoS One. 2017 Dec 15;12(12):e0189354. doi: 10.1371/journal.pone.0189354. eCollection 2017.

6:Male Neobladder.
Authors:Pietzak EJ, Donahue TF, Bochner BH
Institution:Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. New York, NY, USA. New York, NY, USA. Electronic address: bochnerb@mskcc.org.
Journal:Urol Clin North Am. 2018 Feb;45(1):37-48. doi: 10.1016/j.ucl.2017.09.003.

7:Florence robotic intracorporeal neobladder (FloRIN): a new reconfiguration strategy developed following the IDEAL guidelines.
Authors:Minervini A, Vanacore D, Vittori G, Milanesi M, Tuccio A, Siena G, Campi R, Mari A, Gavazzi A, Carini M
Institution:Department of Urology, University of Florence, Florence, Italy.
Journal:BJU Int. 2018 Feb;121(2):313-317. doi: 10.1111/bju.14077. Epub 2017 Dec 11.

8:A Phase III trial of a single early intravesical instillation of pirarubicin to prevent bladder recurrence after radical nephroureterectomy for upper tract urothelial carcinoma (JCOG1403, UTUC THP Phase III).
Authors:Miyamoto K, Ito A, Wakabayashi M, Eba J, Arai Y, Nishiyama H, Sugimoto M, Yamashita R, Kakehi Y
Institution:Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center, Tokyo. Center, Tokyo. Center, Tokyo.
Journal:Jpn J Clin Oncol. 2018 Jan 1;48(1):94-97. doi: 10.1093/jjco/hyx158.

9:The prognostic role of epigenetic dysregulation in bladder cancer: A systematic review.
Authors:Casadevall D, Kilian AY, Bellmunt J
Institution:Cancer Research Program, PSMAR-IMIM (Hospital del Mar Medical Research Institute), Carrer Dr. Aiguader 88, 08003 Barcelona, Spain. Electronic address: dcasadevall@imim.es. Electronic address: anaisyacine.kilian01@estudiant.upf.edu. Institute), Carrer Dr. Aiguader 88, 08003 Barcelona, Spain; Dana-Farber Cancer Institute, 450 Brookline Ave, DANA 1230, Boston, MA 02215, USA. Electronic address: jbellmunt@imim.cat.
Journal:Cancer Treat Rev. 2017 Dec;61:82-93. doi: 10.1016/j.ctrv.2017.10.004. Epub 2017 Nov 6.

10:Atezolizumab in invasive and metastatic urothelial carcinoma.
Authors:Crist M, Balar A
Institution:a Laura & Isaac Perlmutter Cancer Center , NYU Langone Medical Center , New York , NY , USA. Cancer Center , NYU Langone Medical Center , New York , NY , USA.
Journal:Expert Rev Clin Pharmacol. 2017 Dec;10(12):1295-1301. doi: 10.1080/17512433.2017.1389275. Epub 2017 Oct 30.

11:Bladder-sparing Radiotherapy for Muscle-invasive Bladder Cancer: A Qualitative Study to Identify Barriers and Enablers.
Authors:Walker M, Doiron RC, French SD, Feldman-Stewart D, Siemens DR, Mackillop WJ, Booth CM
Institution:Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Ontario, Canada; Department of Oncology, Queen's University, Kingston, Ontario, Canada.; Department of Oncology, Queen's University, Kingston, Ontario, Canada; Department of Urology, Queen's University, Kingston, Ontario, Canada.; Department of Public Health Sciences, Queen's University, Kingston, Ontario, Canada; School of Rehabilitation Therapy, Queen's University, Kingston, Ontario, Canada.; Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Ontario, Canada; Department of Oncology, Queen's University, Kingston, Ontario, Canada; Department of Public Health Sciences, Queen's University, Kingston, Ontario, Canada. Electronic address: boothc@kgh.kari.net.
Journal:Clin Oncol (R Coll Radiol). 2017 Dec;29(12):818-826. doi: 10.1016/j.clon.2017.09.001. Epub 2017 Sep 23.

12:Personalized peptide vaccination as second-line treatment for metastatic upper tract urothelial carcinoma.
Authors:Suekane S, Ueda K, Nishihara K, Sasada T, Yamashita T, Koga N, Yutani S, Shichijo S, Itoh K, Igawa T, Noguchi M
Institution:Department of Urology, Kurume University School of Medicine, Kurume, Japan. Kurume University School of Medicine, Kurume, Japan. Kurume University School of Medicine, Kurume, Japan.
Journal:Cancer Sci. 2017 Dec;108(12):2430-2437. doi: 10.1111/cas.13404. Epub 2017 Oct 12.

13:Alcohol consumption and bladder cancer risk with or without the flushing response: The Japan Public Health Center-based Prospective Study.
Authors:Masaoka H, Matsuo K, Sawada N, Yamaji T, Goto A, Shimazu T, Iwasaki M, Inoue M, Eto M, Tsugane S
Institution:Division of Molecular and Clinical Epidemiology, Aichi Cancer Center Research Institute, Nagoya, Japan.; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.; Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan.; Epidemiology and Prevention Group, Research Center for Cancer Prevention and Screening, National Cancer Center, Tokyo, Japan.; Listed in the Appendix.
Journal:Int J Cancer. 2017 Dec 15;141(12):2480-2488. doi: 10.1002/ijc.31028. Epub 2017 Sep 15.

14:Effects of thiazolidinedione in patients with active bladder cancer.
Authors:Li R, Metcalfe MJ, Ferguson JE 3rd, Mokkapati S, Nogueras Gonzalez GM, Dinney CP, Navai N, McConkey DJ, Sahai SK, Kamat AM
Institution:Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Houston, TX, USA. Houston, TX, USA. Houston, TX, USA. Houston, TX, USA. Houston, TX, USA. Houston, TX, USA. Hopkins University School of Medicine, Baltimore, MD, USA. Cancer Center, Houston, TX, USA. Houston, TX, USA.
Journal:BJU Int. 2018 Feb;121(2):244-251. doi: 10.1111/bju.14009. Epub 2017 Sep 23.

15:The Emerging Role of PD-1/PD-L1-Targeting Immunotherapy in the Treatment of Metastatic Urothelial Carcinoma.
Authors:Gwynn ME, DeRemer DL
Institution:1 Augusta University (AU) Medical Center, Augusta, GA, USA.
Journal:Ann Pharmacother. 2018 Jan;52(1):60-68. doi: 10.1177/1060028017727546. Epub 2017 Aug 23.

16:Comparison of the efficacy and feasibility of laser enucleation of bladder tumor versus transurethral resection of bladder tumor: a meta-analysis.
Authors:Yang H, Wang N, Han S, Male M, Zhao C, Yao D, Chen Z
Institution:Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. zhqchen8366@163.com.; Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. zhqchen8366@163.com.; Department of Urology, Luohe Centeral Hospital, Luohe, Henan province, 462000, China.
Journal:Lasers Med Sci. 2017 Dec;32(9):2005-2012. doi: 10.1007/s10103-017-2308-5. Epub 2017 Aug 23.

For a FREE PREVIEW of the Medifocus Guidebook on Bladder Cancer click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Bladder Cancer click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Bladder Cancer...
at a Special 20% Discount


Medifocus Guidebook on Bladder Cancer

Updated: January 15, 2018
159 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Bladder Cancer is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

BC12956452

Coupon Expires: May 24, 2018



What Our Customers Are Saying...

"My father, a veterinarian, was recently diagnosed with invasive bladder cancer. In wondering how best to support him, I decided to gift him a copy of the MediFocus Guidebook on Bladder Cancer. I knew it would appeal to his "scientific side". I wrote a loving and personal message in the Guide to remind him how much I loved him and then gave it to him. After reading the Guide, he took it to his Urologist and was able to generate excellent and candid questions about his condition."
R.R.
Modesto, California


"This Medifocus Guidebook was significantly helpful at a time that we needed information quickly. We felt we gained information that offered us insight on what to ask our physician, as well as a preview of options on treatment and risk factors that he would probably discuss with us. Emotionally, it's a 'god-send' to look up and receive information immediately. Thanks."
L.H.S.
Crestview, Florida



  
Medifocus Digest Alert is published monthly by Medifocus, Inc.
6810 Park Heights Avenue, Suite C5, Baltimore, MD 21215 USA
Copyright © 2013 Medifocus, Inc. All rights reserved.